Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Promimic

18.95

 

SEK

 

+5.57 %

Less than 1K followers

PRO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
+5.57%
-21.69%
-32.32%
-15.78%
-34.66%
-42.23%
+36.82%
-
+16.39%

Promimic specializes in biotechnology. The company conducts research and development in surface modifications. Examples of specialist areas include surface modifications for osseointegration for orthopedic and dental implants. The main operations are in Europe and America, where research and development are conducted in-house but also through partners.

Read more
Market cap
358.01M SEK
Turnover
3.9K SEK
Revenue
43.98M
EBIT %
-18.92 %
P/E
-
Dividend yield-%
-
Financial calendar
22/8
2025

Interim report Q2'25

19/11
2025

Interim report Q3'25

24/2
2026

Annual report '25

All
Press releases
ShowingAll content types
Regulatory press release5/22/2025, 2:00 PM

Kommuniké från årsstämma 2025 i Promimic AB (publ)

Promimic
Regulatory press release5/15/2025, 5:30 AM

Promimic AB: Strategiska affärer för tillväxt i Kvartal 1 2025

Promimic
Press release5/5/2025, 2:00 PM

Promimic AB: Fördjupat samarbete med Curiteva

Promimic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release4/23/2025, 7:00 AM

Promimic AB: Strategiskt samarbetsavtal med Lincotek

Promimic
Regulatory press release4/17/2025, 5:30 AM

Kallelse till årsstämma i Promimic AB (publ)

Promimic
Regulatory press release4/10/2025, 6:00 AM

Promimic AB: Promimic Årsredovisning 2024

Promimic
Regulatory press release3/3/2025, 10:15 AM

VD:n säljer del av sitt aktieinnehav i Promimic AB (publ)

Promimic
Regulatory press release2/25/2025, 6:30 AM

Promimic AB: Promimic Bokslutskommuniké 2024 och Kvartal 4: All-Time-High

Promimic
Press release2/17/2025, 3:00 PM

Promimic AB: Nya resultat visar att beläggning av implantat med HA[nano] Surface minskar förekomsten av bakterier

Promimic
Regulatory press release11/21/2024, 6:30 AM

Promimic AB: Tillväxt och tio nya godkännanden under tredje kvartalet

Promimic
Regulatory press release10/15/2024, 5:30 AM

Valberedning utsedd i Promimic AB (publ)

Promimic
Regulatory press release10/11/2024, 3:30 PM

Promimic AB: Promimic har löst in optionsprogrammet 2021-TO3

Promimic
Press release9/5/2024, 6:25 PM

Promimic AB: FSG ökar sitt ägande i Promimic

Promimic
Regulatory press release8/22/2024, 5:30 AM

Promimic AB: Nytt försäljningsrekord och nytt licensavtal under andra kvartalet

Promimic
Regulatory press release5/22/2024, 4:00 PM

Kommuniké från årsstämma 2024 i Promimic AB (publ)

Promimic
Regulatory press release5/22/2024, 5:30 AM

Promimic AB: Rekordmånga FDA-godkännanden för Promimics kunder i kvartal 1, 2024

Promimic
Regulatory press release4/26/2024, 12:00 PM

Promimic AB: Promimic Årsredovisning 2023

Promimic
Regulatory press release4/19/2024, 8:27 AM

Kallelse till årsstämma i Promimic AB (publ)

Promimic
Press release3/8/2024, 9:16 AM

Grundarna säljer del av sitt aktieinnehav i Promimic AB (publ)

Promimic
Regulatory press release2/28/2024, 6:30 AM

Promimic AB: Promimic växer med 129 procent under 2023

Promimic
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team